Mustang Bio, INC.: directors' dealings · United States · SEC (Form 4)

About Mustang Bio, INC.

Mustang Bio, Inc. (MBIO) is a clinical-stage biopharmaceutical company listed on the NASDAQ in the United States. The company is focused on developing cell and gene therapies aimed at difficult-to-treat cancers, placing it squarely in the high-risk, high-upside segment of small-cap biotechnology. Mustang Bio was incorporated in Delaware on March 13, 2015, and was founded by Fortress Biotech, giving it an early strategic and financing framework through which to build its pipeline. Today, the company identifies its headquarters in Waltham, Massachusetts, a location that fits well within the US East Coast biopharma ecosystem. Its business model is centered on translational research and clinical development rather than commercial sales. Mustang Bio’s platform has historically included CAR-T programs and other precision-medicine approaches for oncology, with work spanning hematologic malignancies, solid tumors and, in some cases, rare genetic diseases. The company remains a development-stage entity and does not have an approved product on the market. For equity investors, that means the story is primarily about clinical milestones, regulatory progress, funding capacity and dilution risk rather than current operating earnings. In competitive terms, Mustang Bio operates in a crowded field dominated by larger biotech players, academic spinouts and partnership-driven platforms with deeper capital resources. Its potential advantage lies in the selective acquisition and licensing of promising technologies from leading research institutions, allowing it to focus on value creation through targeted development rather than broad commercialization. At the same time, the business remains exposed to the usual biotechnology risks: trial failures, manufacturing complexity, regulatory uncertainty and persistent capital needs. Recent corporate developments have been important for market perception. In early 2025, Mustang Bio addressed Nasdaq listing-compliance issues related to minimum bid price requirements and later announced it had regained compliance. The company also completed a 1-for-50 reverse stock split in January 2025 and raised additional capital during 2025 to support operations. In July 2025, Mustang Bio announced that the US FDA granted orphan drug designation to MB-101 for astrocytomas and glioblastoma, a notable regulatory milestone that may support the long-term investment case if clinical data continue to progress positively. Overall, MBIO remains a speculative NASDAQ-listed US biotech story whose valuation is driven by pipeline execution, financing discipline and milestone delivery.